new peripheral cto crossing & reentry technologies in the ... · arterial cto2 most commonly in...
TRANSCRIPT
New Peripheral CTO Crossing & Reentry Technologies in the
Complex Cases Subhash Banerjee, MD
Associate Professor of Medicine University of Texas Southwestern Medical Center
Chief, Division of Cardiology VA North Texas Health Care System
Dallas, TX
Disclosures • I have the following financial relationships to disclose:
• Type of relation:
– Consultant:
• Covidien (moderate)
• Medtronic (moderate)
– Institutional research grants:
• Gilead
– Ownership interest:
• HygeiaTel
• Mdcare Global (spouse)
• *Type of relation: Consultancy, employment, honoraria, other compensation
• *Level of remuneration: high (over $50,000 yearly), moderate ($10-50,000), modest (< $10,000)
Talking points
Peripheral CTO: prevalence & treatment challenges
Peripheral CTO crossing devices: Viance® & Enteer®
TruPath®
Final results of the PFAST & Re-Open Trials
Duration ≥3 months1
40-50% patients with symptomatic PAD have an arterial CTO2
Most commonly in the infra-inguinal location1
Nearly 50% of SFA lesions present as CTO2
CTO more common in DM2 & CLI1
Often multi-level CTO are present3
Lower Extremity Arterial CTO
1Norgren L et al. J Vasc Surg. 2007; 2Banerjee et al. JACC 2012; 3Banerjee et al. Card. Rev. Med. 2011
Crossing of peripheral CTO is the most common reason for: Failed intervention (13-34%)
Complications (~15%)
Penetration of fibrous cap
Enter distal target vessel True lumen entry
Use of re-entry device
Navigate collaterals & side-branches
Long segment/multi-level occlusions
Lack of crossing device maneuverability Pushability
Torque control
Trapping
Guide-wire control
Treatment Challenges of LE CTO
Jacobs et al. J Vasc. Surg. 2006; 43(6): 1291
Approved
Devices
Frontrunner® Safe-Cross® Crosser® Wildcat® TruePath®
Technique Blunt micro-
dissection Guidance, ablation
and crossing
High frequency mechanical
vibration
Rotational spinning
Self-rotating guide wire
Length 82 cm, 132 cm 175 cm, 275 cm 146 cm 110 cm 165 cm
Sheath 6F 6F 5F, 6F (rapid exchange)
6F 6F
Support
catheter 4.5 F micro-guide
No support catheter
1.8 mm Usher support catheter
No support catheter
No support catheter
Guide wire 0.035 inch 0.014 inch and
0.035 inch 0.014 inch and
0.018 inch 0.035 inch 0.018 inch
Crossing
profile
0.99 mm with actuating jaws that
open to 2.3 mm 0.89 mm 1.1 mm 2.0 mm 0.43 mm
Viance® & Enteer® CTO crossing & re-entry system
Distal Catheter Tip (atraumatic, 0.037”)
0.014” guidewire (300 cm)
135 cm shaft (2.3F) 0.035 OD: compatible with most support catheters
Viance® Peripheral Blunt Micro-dissection Catheter
Ratchet handle for fast-spin & tactile feel
Multi-wire coiled shaft for true 1:1 torque
Mechanism of Action - Fast Spin Device Locates Microchannels in CTO
8 |
The spinning motion of the Viance™ Crossing Catheter reduces orthogonal friction: 1. Finds microchannels through
a CTO 2. Provides blunt dissection
through a CTO 3. Use of a directional
“steering” wire
The Enteer™ Re-entry System Re-enter True Lumen from Sub-intimal Channel
Offset exit ports for Stingray CTO Re-Entry
Guidewire
Stingray CTO Re-Entry Guidewire Probe
Self-orienting balloon has flat shape
2.9F shaft profile
Compatibility:0.014" guidewire6F guide catheter
Initial unsuccessful attempt
Contralateral CFA access 6F Crossover sheath Primary GW/support catheter crossing
Poor distal filling Gradual escalation of Symptoms after failed attempt
Primary crossing with Viance catheter
Right lateral view
Subintimal passage and re-entry with Enteer
Successful TP trunk re-entry with Enteer catheter & wire Followed by IVUS confirmation
IVUS confirmation of distal true lumen access
Compressed true lumen atheroma
Sub-intimal space s/p balloon dilation
Final result after distal SFA & TP trunk stenting
6x40mm Nitinol Self-expanding stent implantation
Two 3x20 mm & 3x18 mm overlapping coronary DES implantation
Significant improvement in patient symptoms at 3m F/U
Viance & Enteer Peripheral CTO Crossing Solutions
Strengths • Controlled advancement • Predictable distal tip
handling - alter tip strength & pushability
• No external controller • ATK & BTK options • Shorter procedural duration • Lower complications
Limitations • “Over-spinning” • Flush ostial occlusions
require a “steering guide wire”
• Limited aspiration capability
No capital equipment
Peripheral Facilitated Antegrade Steering Technique in Chronic Total Occlusions (PFAST-CTOs)
Design: Prospective, multi-center non-randomized clinical trial
Primary Safety Endpoint: Major Adverse Event (MAE) at 30d: Death, unplanned major amputation, perforation & TLR
Primary Effectiveness Endpoint: Technical Success: Distal true lumen access
Peripheral Facilitated Antegrade Steering Technique in Chronic Total Occlusions (PFAST-CTOs)
105 Subjects (failed wire crossing)
39 Subjects Screen Failures
66 Subjects with CTOs
21 Subjects Enteer Cases
45 Subjects Viance Cases
Rutherford category 3-4=73% CTO length=19.5 ± 10.8 cm SFA CTO=65% BTK CTO=32%
PFAST: Primary Safety Endpoint
Major Adverse Event Rate at 30 Days Overall
(n= 66)
Overall MAE 3.0% (2/66)
Death 0.0%
Unplanned Amputation 0.0%
Target Lesion Revascularization
Bypass Surgery
Percutaneous Intervention
1.5% (1/66)
0.0%
1.5% (1/66)
Perforation 1.5% (1/66)
PFAST: Primary Effectiveness Endpoint
Technical Success
Overall (n= 66) 85% (56/66)
Viance Only Cases (n= 45) 84% (38/45)
Enteer Cases (n= 21) 86% (18/21)
TruPath® Peripheral CTO Crossing Device
Designed to cross fibro-calcific CTO
Diamond-coated distal tip rotates at 13,000 rpm on a 0.018” guidewire
Requires no capital equipment
Extension capability to 335 cm
ReOpen Trial: TruePath™
98.8
80.0
0
20
40
60
80
100
Device success (n=85) Freedom 30d MAE (n=85)
%
Femoro-popliteal (FP)/BTK CTO with initial failed guide-wire crossing
Primary endpoint: success of crossing
Secondary endpoint: safety at 30-days
CTO length = 166 mm
SFA = 71.8%
Popliteal/FP= 15.3%
Tibial= 12.9%
A Multicenter Experience Evaluating Chronic Total Occlusion Crossing with the TruePath™ (Prospective Multi-center Trial)
Failed guidewire attempt
Concluding Message
Peripheral CTO can be effectively tackled with predictably high success rates and low complications
Viance®/Enteer® & TruPath® device facilitated CTO crossing into the distal true lumen in >80% of cases after primary guidewire failure